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SUMMARY
Clinical evidence suggests that benign cartilage lesions can progress to malignant chondrosarcoma, but the
molecular events in this progression are unknown. Mice that develop benign cartilage lesions due to overex-
pression of Gli2 in chondrocytes developed lesions similar to chondrosarcomas when they were also
deficient in p53. Gli2 overexpression and p53 deficiency had opposing effects on chondrocyte differentiation,
but had additive effects negatively regulating apoptosis. Regulation of Igfbp3 expression and insulin-like
growth factor (IGF) signaling by Gli and p53 integrated their effect on apoptosis. Treatment of human chon-
drosarcomas or fetal mouse limb explants with IGFBP3 or by blocking IGF increased the apoptosis rate, and
mice expressing Gli2 developed substantially fewer tumors when they were also deficient for Igf2. IGF
signaling-meditated apoptosis regulates the progression to malignant chondrosarcoma.INTRODUCTION
The progression of neoplasia from a benign lesion to malignancy
is thought to require the progressive accumulation of mutations
deregulating cell growth control, apoptosis, and DNA stability.
Although this progression is identified in tumors of epithelial
origin, it has not been demonstrated in mesenchymal tumors,
in part because benign precursor lesions for most sarcomas
are not clearly identified. This is not the case for enchondromas,
which are benign cartilaginous tumors located in the metaphysis
of bone. Enchondromas can occur as isolated or multiple lesions
and can progress to malignant chondrosarcoma, an event that
occurs at a higher rate in multifocal diseases. Although the
factors implicated in the progression to chondrosarcomas are
poorly understood, cytogenetic andmutational analysis of tumor126 Cancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc.suppressor genes identified mutations or cytogenetic anomalies
in the p53 gene in roughly a third of chondrosarcomas (Benini
et al., 2006; Oshiro et al., 1998), suggesting that tumor
suppressor gene inactivation is important in the transformation
of enchondromas to malignant sarcomas. p53 regulates cell
cycle progression and apoptosis (Komarova et al., 1997), acting
as a transcription factor to regulate the expression of genes such
as p21 and GADD45 and interacting with proteins such as the
proapoptotic member of the Bcl2 family, Bax (Kobayashi et al.,
2002; Reinke and Lozano, 1997; Srinivasula et al., 1998).
Bone development depends on proper coordination of spatial
and temporal control of cell function. The growth plate is an inte-
gral component of endochondral bone development and is also
responsible for postnatal longitudinal growth. Growth plate
chondrocytes undergo an orderly process of proliferation andSIGNIFICANCE
Although molecular mechanisms responsible for the progression of benign to malignant tumors of epithelial origin have
been identified, they have not been demonstrated in mesenchymal tumors. Here, we used a mouse model of enchondro-
matosis to show that p53 deficiency can cause chondrosarcomas to arise from benign lesions. An unexpected role for
IGFBP3 in this progression was found. Human cartilage tumors have low levels of IGFBP3 expression, compared to normal
chondrocytes, with chondrosarcomas having lower levels than benign lesions, suggesting that IGFBP3 level is a prognostic
factor in cartilage tumors. Furthermore, IGFBP3 treatment or IGF signaling blockade increased chondrosarcoma apoptosis,
suggesting a therapeutic approach to chondrosarcomas, a tumor for which there is no universally effective chemotherapy.
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Gli2 and p53 in Cartilage Tumor Progressiondifferentiation, ultimately resulting in the production of extracel-
lular matrix components, such as type X collagen (ColX), and
programmed cell death. Bone forms initially in the central part
of the bone, adjacent to the metaphyseal growth plate.
Secondary ossification sites arise at the epiphyseal ends of the
bone and progress toward the center of the bone shaft, eventu-
ally leading to closure of the growth plate at maturity. This
process is tightly regulated by a number of signaling pathways
that maintain the normal rate of endochondral bone growth (Bal-
lock and O’Keefe, 2003).
Because of their location adjacent to the growth plate, it has
long been suspected that enchondromas arise from rests of
growth plate chondrocytes that fail to undergo terminal differen-
tiation. This notion is supported by the development of metaphy-
seal cartilage rests, similar in nature to enchondromas in humans,
in transgenic mice expressing either a mutant PTHR1 or the
hedgehog (Hh)-activated transcription factor Gli2 in chondro-
cytes (Hopyan et al., 2002). PTHrP and theHh signaling pathways
play important roles in regulating growth plate chondrocyte
differentiation. Activation of the PTHrP pathway delays chondro-
cyte differentiation (Amizuka et al., 1994; Karaplis et al., 1994;
Vortkamp et al., 1996), resulting in a downregulation of expres-
sion of the Hh ligand, Indian Hedgehog (Ihh), by hypertrophic
chondrocytes (Lanske et al., 1996). Ihh regulates chondrocyte
proliferation and differentiation though direct regulation of Gli
transcription factors and by regulating PTHrP ligand expression
(Kobayashi et al., 2002; Koziel et al., 2005; Mau et al., 2007). As
such, these signaling pathways act in a feedback loop regulating
differentiation. In the case of enchondromatosis, there is deregu-
lation of this feedback loop, resulting in constitutive activation of
Hh signaling, even in the presence of PTHrP stimulation and
Gli-mediated transcriptional activation (Hopyan et al., 2002;
Tiet et al., 2006).
Although malignant and benign cartilage lesions exhibit
constitutive Gli-mediated transcription, the level of Gli transcrip-
tional activation is similar for both tumor types, suggesting that
while constitutive Hh signaling is a common finding in cartilage
tumors, a higher level of activation is not responsible for malig-
nant progression (Tiet et al., 2006). Other factors, such as inac-
tivation of tumor suppressor genes, are thus likely important in
cartilage tumor progression. As such, the aim of this study was
to investigate the effect of p53 deficiency on the progression of
enchondromas.
RESULTS
Deficiency of p53 in Gli2-Transgenic Mice Predisposes
to the Development of Larger, More Cellular, Cartilage
Lesions
We utilized a mouse model of enchondromatosis in which the
Hh-activated transcription factor, Gli2, is expressed in chondro-
cytes driven by the regulatory elements of type two collagen,
Tg(Gli2;ColIIAI) (Hopyan et al., 2002). The tumors in these mice
develop on the basis of amolecular feature that is common in en-
chondromas—constitutive activation of Gli-mediated transcrip-
tion—and, as such, they are an applicable model for the human
disorder. To determine whether p53 deficiency alters the
neoplastic phenotype of cartilage lesions, Tg(Gli2;ColIIAI) mice
were crossed with mice expressing a null p53 allele (Jackset al., 1994). The cartilage tumor phenotype was compared bet-
ween Tg(Gli2;ColIIAI);p53+/mice and littermate Tg(Gli2;ColIIAI);
p53+/+ mice. Since the metaphyseal cartilage lesions occurring
in Tg(Gli2;ColIIAI)mice are observed at greatest frequency about
the distal femur, we examined longitudinal sections of the bone
for histological comparison. Three sections, equally distributed
across the knee, were analyzed from each limb to allow for a
systematic analysis. Cartilaginous lesions were identified in all
of the mice. There were an average of 5.8 ± 2.3 lesions in the
growth plate of Tg(Gli2;ColIIAI);p53+/+ mice. These lesions
measured under 0.5 mm in diameter (mean diameter, 0.32 ±
0.12 mm) and were composed of cells with occasional binu-
cleate lacunae in a cartilage matrix. There were 12.3 ± 3.8 cells
per high-powered field in the lesions (Figures 1A and 1C).
Some of the lesions were connected to the growth plate through
columns of cartilage. These lesions were identified in mice at all
ages observed, up to 12 months of age.
In contrast, Tg(Gli2;ColIIAI);p53+/ mice developed larger
(greater than 1mm in diameter) cartilage lesions (mean diameter,
1.7 ± 0.3 mm) (Figures 1B and 1D). They were frequently in
contact with the growth plate and had increased cellularity,
compared to the smaller lesions (23.4 ± 7.8 cells per high-pow-
ered field). These cells showed variability in cytological appear-
ance, seeming to have a broad range of characteristics of chon-
drocytes present during development (Figure 1F). There were
pleiomorphic nuclei in many of the cells. These lesions were not
observed in mice at 2 months of age, but were identified in a
larger proportion of mice at subsequent time points. At 1 year
of age, 50% of mice exhibited these lesions (Figure 1E). The
appearance of the larger lesions did not change with the age
of the mice (Figure 1E). Overall, this appearance is similar to
that of a low-grade chondrosarcoma. We did not find a loss of
the normal p53 allele in these larger lesions, as determined using
a PCR-based technique (Figure 1I). The level of p53 expression
was roughly half that of Tg(Gli2;ColIIAI);p53+/+ littermates, sug-
gesting normal expression from the wild-type allele (Figure 1J).
In a small number of mice (6%), a larger lesion (>1 cm in diam-
eter) arose from bone, extending into the soft tissues. These
lesions had a cytological appearance consistent with a higher
gradesarcoma,composedof spindle-likecells (Figure 1G). These
lesions showed loss of heterozygosity for the wild-type p53 allele
and exhibited a lack of p53 RNA expression (Figures 1I and 1J).
p53 and Gli2 Interact to Regulate Chondrocyte
Proliferation and ColX Expression
in the Fetal Growth Plate
To determine whether the change in phenotype was due to alter-
ations in proliferation or differentiation, we examined these
parameters in the tumors and distal femurs of fetal limbs. Prolif-
eration was examined in the tumors using phosphohistone H3
staining, showing a trend toward a greater percentage of stained
cells in the larger lesions that developed in the Tg(Gli2;ColIIAI);
p53+/ mice, compared with lesions in Tg(Gli2;ColIIAI);p53+/+
mice. There was also little difference in the proportion of cells
staining for ColX. We examined these same parameters in the
growth plate from mature mice and also did not observe
substantial differences. Since changes in chondrocyte behavior
that could be responsible for the changes in the tumor pheno-
type may be more readily apparent in fetal limbs, we examinedCancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc. 127
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(A–G) Histology of tumors in mice overexpressing Gli2 (Tg(Gli2;
ColIIAI);p53+/+) and Gli2-overexpressing mice also deficient in
p53 (Tg(Gli2;ColIIAI);p53+/). Safranin O staining (A and B) or
hematoxylin and eosin staining (C–G) is shown. Tg(Gli2;ColIIAI);
p53+/+ mice demonstrate lesions in the metaphysis that are under
0.5 mm in diameter, are composed of cells with occasional binu-
cleate lacunae in a cartilage matrix, and have an appearance not
unlike that seen in human enchondromas (A and C). Tg(Gli2;
ColIIAI);p53+/ mice developed larger lesions, greater than 1 mm
in diameter (B and D). Lesions that were identified in mice at
different ages have a similar appearance, as illustrated by a lesion
in a 4-month-old (D) and a 12-month-oldmouse (E). Higher magni-
fication shows that these larger cartilage lesions have increased
cellularity, variability in cytological appearance, pleiomorphic
nuclei in many of the cells, and an appearance similar to that of
a low-grade chondrosarcoma (F). A small number of mice devel-
oped lesions with a soft tissue mass; a histologic appearance
consistent with an undifferentiated sarcoma developed in some
of the mice, in association with loss of the wild-type p53 allele (G).
(H) Kaplan-Meier survival curve showing the proportion of mice
that develop large cartilage lesions at various ages.
(I) The wild-type alleles are lost in the undifferentiated mesen-
chymal lesions with a soft tissue mass, but not in other cartilage
lesions.
(J) Quantitative RT-PCR showing relative level of p53 expression,
compared with the growth plate from Tg(Gli2;ColIIAI);p53+/+ or
Tg(Gli2;ColIIAI);p53+/ mice. There is a level of expression in
p53+/ mice that is about half the level in p53+/+ mice. There is
a similar level of expression in the cartilage lesions that formed,
compared with the growth plates, regardless of the genotype.
There is a substantial decline in the level of expression in the undif-
ferentiated mesenchymal lesions that are associated with a soft
tissuemass. Data are given asmeans and error bars as 95%confi-
dence intervals.E16.5 limbs. Tg(Gli2;ColIIAI) mice had a smaller zone of ColX
staining, a finding that was consistent with previous studies of
the phenotype of this mouse. Mice deficient in p53 had a larger
zone of ColX expression than did wild-type mice, and, surpris-
ingly, mice overexpressing Gli2 in the growth plate and deficient
in p53 had an even larger zone of ColX expression (Figures 2A
and 2B).
In the fetal limbs, we found that Ki67 staining was a more
reproducible marker of proliferation. The relative length of the
growth plate, length of the zone expressing ColX, length of the
zone staining for Ki67, and proportion of Ki67-stained cells
from the distal femur were examined. The length of the prolifer-
ative zone (zone with Ki67 staining) did not change significantly
with overexpression of Gli2 or alteration of p53 protein levels.
Within the proliferative zone, there was a trend toward an
increase in the percentage of Ki67-stained cells in mice overex-
pressing Gli2 or in mice deficient in one or both p53 alleles
(Figure 2C).
Chondrocyte Apoptosis Is Regulated by Both
Gli-Mediated Transcription and p53
The decrease in the height of the region of the growth plate
expressing ColX in Gli2-overexpressing mice is consistent with
the notion that enchondromas are associated with an inhibition
in chondrocyte differentiation, maintaining some growth plate
chondrocytes in a less-differentiated state. These cartilage128 Cancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc.islands are left behind as the bone grows, becoming entrapped
in the developing metaphysis. The change in ColX staining in the
distal femurs from Gli2-transgenic, p53-deficient mice is, at first
glance, at odds with this notion, because an extended region of
staining in these mice suggests that cells are entering terminal
differentiation at an accelerated rate. However, another possi-
bility is that the larger region of ColX staining is due to a block
to cells exiting this zone. Cells could leave this region of the
growth through programmed cell death. Inhibition of apoptosis
could thus explain the increased zone of ColX staining and could
also be responsible for the development of the larger cartilage
lesions. To test for this possibility, we examined the expression
of markers of apoptosis in the fetal growth plates. The per-
centage of cells exhibiting either TUNEL or active caspase-3
staining was moderately decreased in the growth plate of both
Gli2-overexpressing and p53/ mice. However, both TUNEL
staining and active caspase-3 staining were substantially
decreased in Tg(Gli2;ColIIAI);p53/ mice (Figures 3A, 3B, and
3C). Thus, p53 and Gli2 cooperate to regulate apoptosis in chon-
drocytes, with Gli2 being a negative regulator and p53 a positive
regulator of this process. The length of the ossified portion of the
fetal femurs was compared with the overall bone length. There
was a decrease in the proportion of ossified bone in the limbs
showing a decrease in apoptosis, supporting the notion that
decreased apoptosis is the cause of the increase in length of
ColX staining (Figure 3D).
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Neoplasia
Gene profiling was used to identify genes differentially regu-
lated under PTHrP stimulation by the R150C variant PTHR1,
a mutant PTHrP receptor found in rare cases of enchondroma-
tosis (Hopyan et al., 2002; Couvineau et al., 2008). Gene
Figure 2. p53 and Gli2 Regulate Growth Plate Prolifera-
tion and ColX Expression in the Growth Plate
(A and B) The length of the region of the growth plate exhibiting
ColX staining, a measure of differentiation. Representative histo-
logical sections are shown (A). The height of the region exhibiting
ColX staining in Tg(Gli2;ColIIAI)micewas significantly smaller than
that in wild-type (WT) mice, whereas p53/ mice had a longer
zone than did WT mice, although this did not reach statistical
significance. Tg(Gli2;ColIIAI);p53/ mice had an significantly
longer zone of ColX expression than did WT mice. Graphical
representation of the heights of the ColX staining in the growth
plates, with data given as means and 95% confidence intervals,
is also shown (B). Asterisks are above data that are significantly
different from WT mice.
(C) Proliferation asmeasured by average percentage of Ki67-posi-
tive cells in the various genotypes and error bars as 95% confi-
dence intervals, although these did not reach statistical signifi-
cance.
Figure 3. p53 and Gli2 Regulate Growth Plate
Apoptosis
(A) Representative histologic sections. The arrows show
positively stained cells.
(B and C) Number of TUNEL-positive and caspase-3-posi-
tive cells was compared between Tg(Gli2;ColIIAI);p53/,
Tg(Gli2;ColIIAI);p53+/+, and p53/ littermate mice. There
was a decrease in both TUNEL and active caspase-3
staining in Tg(Gli2;ColIIAI) and p53/ mice, compared
with WT mice, and there was a further increase in staining
in Tg(Gli2;ColIIAI);p53/ mice. Data are given as means
and 95% confidence intervals. Asterisks are above data
that are significantly different from both Tg(Gli2;ColIIAI or
p53/ mice.
(D) The ratio of the ossified to total length of the bone.
Asterisks are above data that are significantly different
from both Tg(Gli2;ColIIAI or p53/ mice.
expression was compared between C3H10T1/2 cells
stably transfected with either the R150C variant
PTHR1 or a wild-type PTHR1, using a technique
described elsewhere (Mau et al., 2007). A small
number of genes were differentially regulated by at
least 3-fold. One of the genes identified, a known
p53 target, was Igfbp3. The differential expression
of this gene was confirmed in the cell lines using quantitative
RT-PCR.
To determine whether IGFBP3 was differentially regulated in
human cartilage tumors, we examined 6 enchondromas and
29 chondrosarcomas of various grades and compared the level
of expression with normal growth plate cartilage from 4 patients.Cancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc. 129
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mas and a further decrease in the level of expression in chondro-
sarcomas (Figure 4A). Importantly, there was a lower level of
expression in high-grade lesions than in lower-grade lesions.
Immunohistochemistry using an anti-IGFBP3 antibody con-
firmed the decreased protein level in patient samples (Figure 4B).
IGFPB-3 Expression Is Regulated by Gli-Mediated
Signaling
Although previous studies showed that IGFBP3 expression is
regulated by p53, it is not known whether Gli-mediated tran-
scription could also regulate its expression. The Mulan website
(http://mulan.dcode.org) was used to examine the promoter
region of IGFBP3 (Villafuerte et al., 1997). A Gli consensus
sequence-binding region that was conserved between humans
and mice was identified 1.2 kb upstream of the start site
(Figure 5A). Chromatin immunoprecipitation (ChIP) with primer
pairs adjacent to this potential binding site and an antibody to
Gli2 showed that Gli2 could bind to this site (Figure 5B). To deter-
mine whether Gli2 and p53 would regulate expression of Igfbp3
in vivo, its expression in the cartilage from E16.5 distal femurs
of Tg(Gli2;ColIIAI);p53/, Tg(Gli2;ColIIAI);p53+/+, p53/, and
wild-type littermate mice was examined. Both p53 and Gli
independently regulated Igfpb3, with p53 acting as a positive
regulator and Gli acting as a negative regulator of expression
(Figure 5C). Explant cultures of chondrosarcoma tumors were
established as reported elsewhere (Tiet et al., 2006), and it was
found that stimulation with Hh ligand downregulated expression
of IGFBP3, whereas treatment with an Hh neutralizing antibody,
or cyclopamine, which blocks Hh signaling downstream of its
receptor, upregulated its expression, compared with controls
(Figure 5D). To determine whether hedgehog signaling would
Figure 4. IGFBP3 Is Expressed at Low Levels in Cartilage Tumors
(A) Using quantitative PCR, there was a lower level of expression of IGFBP3 in
cartilage lesions, compared with that in normal growth plates. The level of
expression was lower in benign enchondromas than in normal growth plate
cartilage, but was even lower in chondrosarcoma. Data are given as means
and 95% confidence intervals. An asterisk above a data point shows a signifi-
cant difference from the level of expression in enchondromas.
(B and C) IGFBP3 immunohistochemistry showed a lower level of expression
in a low-grade chondrosarcoma (B) than in a growth plate chondrocyte (C).130 Cancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc.directly regulate IGFBP3 expression, a 1.8 kb promoter
construct driving luciferase (Cohick et al., 2000) was transfected
into NIH 3T3 cells, which were treated with cyclopamine or
hedgehog ligand. Hh blockade activated the reporter construct,
andHh ligand decreased its activity. IGF stimulation was used as
a positive control (Figure 5E). Using site-directed mutagenesis,
this binding site was obliterated, and Hh modulation no longer
regulated the reported construct activation, whereas IGF stimu-
lation still caused activation.
IGFBP3 Regulates Apoptosis in the Growth Plate
and Neoplastic Chondrocytes
IGFBP3 is known to promote apoptosis and inhibit cell growth in
various tissue types (Bhattacharyya et al., 2006; Lee et al., 2005).
Studies in chondrocyte cell cultures show a complex relationship
between IGFBP3 and IGF in the regulation of proliferation;
however, its effect on apoptosis has not been investigated
(Kiepe et al., 2002). To examine its function in the growth plate
and in cartilaginous neoplasia, we treated wild-type and trans-
genic limb explants with recombinant IGFBP3. Wild-type mice
did not show a difference in proliferation, apoptosis, or size of the
zone expressing ColX following IGFBP3 treatment. In contrast,
although there was not a significant difference in cell proliferation
in Gli2-transgenic, p53-deficient mice with IGFBP3 treatment,
there was a substantial increase in the rate of apoptosis as
measured by the number of cells exhibiting TUNEL or active cas-
pase-3 staining. There was also a smaller zone of ColX staining.
Indeed, IGFBP3 treatment increased the apoptosis rate to a level
similar to that found in wild-type mice (Figure 6). To determine
whether IGFBP3 could function in a similar manner in neoplastic
chondrocytes, we treated chondrosarcoma cells with IGFBP3
and found that this treatment substantially increased tumor cell
apoptosis, as determined using TUNEL staining and caspase-3
activity (Figures 7A, 7B, and 7C). To better determine whether
IGFBP3 mediates the effects of p53 and Hh signaling on
apoptosis, primary chondrosarcoma cells were transfected
with either a p53 expression vector, an siRNA construct targeted
to IGFBP3, or control vectors, and then were treated with either
the Hh-neutralizing antibody, IGFBP3, or controls. Apoptosis
was determined using annexin V staining, as detected using
flow cytometry. There was a substantial increase in the propor-
tion of cells exhibiting annexin V staining when expressing p53
and treated with an Hh-neutralizing antibody. In cells expressing
siRNA for IGFBP3, therewas no change in apoptosis, suggesting
that IGFBP3 mediates the effect of Hh and p53 on apoptosis.
Treatment of the primary cell culture with IGFBP3 alone
increased the apoptosis rate to about the same level as in cells
expressing p53 and treated with cyclopamine (Figure 7D). Taken
together, these results show that IGFBP3 mediates the effect of
p53 and Hh signaling in chondrocytes.
IGFBP3 Regulates Apoptosis through
an IGF-Mediated Mechanism
One mechanism by which IGFBP3 can regulate apoptosis is
through its interaction with IGF, resulting in the inhibition of IGF
signaling through a receptor-mediated mechanism (Kim et al.,
2004; Rajah et al., 1997; Silha et al., 2006). To determine whether
IGFBP3 mediates IGF signaling, we examined the regulation of
insulin receptor substrate-1 (IRS-1) phosphorylation at Y612
Cancer Cell
Gli2 and p53 in Cartilage Tumor ProgressionFigure 5. Gli Transcriptional Activation Regulates
IGFBP3 Expression
(A) Diagrammatic representation of the IGFBP3 gene,
including the promoter region, showing a Gli consensus
binding site 1.2 kb downstream of the start site (from
MULAN analysis). The binding site is in a DNA region
conserved between multiple species.
(B) ChIP shows amplification of the Gli-binding site in the
IGFBP3 promoter with use of the Gli-2 antibody but not
the control DNA. Additional controls included a second
set of primers that crossed the Gli-binding site (positive)
and a second set of primers amplifying a randomly
selected DNA sequence on the same chromosome
(negative).
(C) Igfbp3 expression in fetal limbs from various mice as
determined using quantitative PCR. Data are given as
means and 95% confidence intervals. There was a signif-
icantly different level of expression between WT mice
and each of the genotypes (as indicated with an asterisk
above the data) and a significant difference between
either the P53/;GLI-2 mice or WT mice, compared
with either P53/- or Gli-2-transgenic mice (indicated
by a number sign above the data point), showing an
additive effect of Gli2 and P53/ on Igfbp3 expression
level.
(D) IGFBP3 expression level in a chondrosarcoma cell
culture treated with Hh blockade using cyclopamine,
Hh ligand, tomatadine as a control. Data are given as
means and 95% confidence intervals, an asterisk above
the data shows significant difference from tomatadine.
(E) Relative luciferase activity produced by an IGFBP3
promoter reporter constructs. Data are given as means
and 95% confidence intervals. There is a significant
difference in activity between Hh blockage and stimu-
lation, compared with control conditions in the WT construct, but no change in the mutant construct lacking the Gli consensus binding site. An asterisk
above the data shows significant difference from tomadaine. IGF treatment is a positive control.(Yamanaka et al., 1997). Protein isolated from cartilage of fetal
limbs showed that phospho-Y612 IRS level is increased in
Gli2-transgenic and p53/ mice, compared with wild-type
mice (2.5 and 2.8 times, respectively; p = 0.02). The phosphory-
lation level is further elevated in p53/ mice that also express
Gli2 (3.9 times control; p = 0.01) (Figure 8A). To determine
whether IGFBP3mediates IRS-1 phosphorylation in chondrosar-
comas, explant cultures were treated with IGFBP3, and this
treatment inhibited IRS-1 phosphorylation (Figure 8B). This
finding raises the possibility that IGFBP3 is acting through IGF
ligand blockade to regulate apoptosis. Limb explants were
treated with either IGFBP3 or neutralizing antibodies to IGF-1
and IGF-2. Treatment with neutralizing antibodies caused a
similar change in apoptosis, as measured using TUNEL or cas-
pase-3 staining (Figures 8C and 8D). To determine whether
IGF blockade would have a similar effect in chondrosarcomas,
explants were treated with either IGFBP3 or IGF neutralizing anti-
bodies. There was a similar increase in apoptosis rate with IGF
blockade as with IGFBP3 treatment (Figures 8E and 8F). To
determine whether IGF ligands would have an effect on cartilage
tumor formation, the Tg(Gli2;ColIIAI) mouse was crossed with
an Igf2+/ mouse (DeChiara et al., 1990) to generate Tg(Gli2;
ColIIAI);Igf2+/ mice and Tg(Gli2;ColIIAI);Igf2+/+ littermates.
There was a substantial decline in the number of cartilage lesions
that developed in the mice deficient in IGF2 (Figure 8 G). In addi-
tion, the apoptosis rate in growth plate chondrocytes was higher
in mice heterozygous for Igf2 (Figures 8H and 8I). Takentogether, these data suggest that the effect of IGFBP3 on its
regulation of chondrocyte apoptosis is related to its ability to
inhibit IGF signaling.
DISCUSSION
The cartilage lesions in mice that overexpress Gli2 in chondro-
cytes likely occur because some growth plate cells fail to
undergo apoptosis and remain behind in the developing bone.
The absence of progression of these lesions in mice, in concert
with data from human tumors showing a similar level of expres-
sion of Hh-regulated genes in both benign and malignant lesions
(Tiet et al., 2006), suggests that constitutive Hh signaling activa-
tion in chondrocytes on its own is not sufficient to cause a malig-
nant cartilage tumor. Here, we demonstrate that the loss of one
p53 allele in Gli2-transgenic mice causes the development of
lesions similar to low-grade chondrosarcomas. Furthermore,
higher-grade sarcomas developed in association with somatic
loss of both p53 alleles. Thus, additional genetic events are
necessary for the progression of benign cartilage tumors.
Growth plate chondrocytes differentiate in a tightly regulated
manner. While it is thought that apoptosis is responsible for the
disappearance of chondrocytes at the end of terminal differenti-
ation, alternative explanations, such as transdifferentiation of
chondrocytes to other cell types, have been proposed (Eren-
preisa and Roach, 1996; Kahn and Simmons, 1977). Enchondro-
mas that develop in mice are associated with an inhibition ofCancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc. 131
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ifested by a smaller zone of ColX expression in fetal limbs
(Hopyan et al., 2002). We found that mice overexpressing Gli2
that are also deficient in p53 develop enchondromas as well as
lesions similar in histological appearance to low-grade chondro-
sarcomas. Surprisingly, the fetal growth plate in these mice
shows an increased length of ColX expression. One explanation
for this phenotype is that cells are delayed from leaving the zone
of ColX by an inhibition of apoptosis. Our data showing an
inverse relationship between apoptosis rate and length of ColX
Figure 6. IGFBP3 Regulates Cell Apoptosis and ColX
(A) Representative histologic sections of explant cultures from fetal limb
explants shows that IGFBP3 treatment upregulates cell apoptosis and regu-
lates the length of ColX expression in fetal limbs. A positive apoptotic cell is
labeled with an arrow.
(B) The rate of apoptosis, Ki67 staining, and length of ColX staining in
Tg(Gli2;ColIIAI);p53/ limbs. Data are given as means and 95% confidence
intervals. Asterisks are above data that are significantly different from WT
mice. Apoptosis and ColX staining in Tg(Gli2;ColIIAI);p53/ limbs returns
towardWT levels with IGFBP3 treatment. Treatment ofWT limbs had aminimal
impact, suggesting a threshold effect of IGFBP3.132 Cancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc.staining in these mice suggest that apoptosis is indeed respon-
sible for chondrocytes exiting the zone of terminal differentiation.
One possible mechanism by which Gli and p53 could act to
modulate changes in apoptosis is through the combined regula-
tion of expression of a common target gene. We identified
IGFBP3 as a gene that is differentially regulated by both Gli-
mediated signaling and p53. While IGFBP3 is known to be ex-
pressed in the growth plate (Olney and Mougey, 1999; Parker
et al., 2007), its function in growth plate regulation had not previ-
ously been elucidated. Fetal limb explant experiments showed
that IGFBP3 regulates chondrocyte apoptosis. It is possible
that in the normal growth plate, IGFBP3 expression acts to
sequester IGF near the zone of terminal differentiation, allowing
normal apoptotic cell death. Such a function may explain
previous cell culture data showing a lack of effect of IGFBP3 in
regulating cell proliferation after IGF stimulation in terminally
differentiated chondrocytes, whereas it has such an effect in
proliferating chondrocytes (Kiepe et al., 2002; Spagnoli et al.,
2001), as the overriding function of IGFBP3 in terminally differen-
tiated cells may be to allow for cell death.
IGFBP3 can promote apoptosis and inhibit cell growth in
various tissue types (Jenkins et al., 2005; Kiepe et al., 2002; Lee
et al., 2002; MacLean et al., 2003; Shim et al., 2004; Silha et al.,
2006; Spagnoli et al., 2001) through IGF-dependent or -indepen-
dent mechanisms. As a carrier of free IGFs, IGFBP3 may inhibit
cell survival by sequestering IGFs from activating IGF receptors.
Given that IGFBP3 regulates IRS phosphorylation and induces
similar apoptotic changes in chondrocytes to that of IGF-neutral-
izing antibody treatment, it is possible that, in these cell types,
IGFBP3 acts through IGF to regulate aptotosis. Nevertheless,
there are other potential mechanisms by which Hh signaling
can regulate apoptosis. In vitro studies have suggested a direct
modulation of transcriptional activity of proapoptotic Bcl-2 (Bar
et al., 2007; Bigelow et al., 2004; Kasper et al., 2006; Louro
et al., 2002) and, more recently, the posttranscriptional stabiliza-
tion of Bcl-2 andBcl-XL that is dependent onPI3-kinase signaling
(Morton et al., 2007).
Hh signaling could regulate IGF activity through other mecha-
nisms. For instance, Hh signaling in medulloblastoma precursor
cells acts through mTOR to regulate IGFR-1 signaling (Parathath
et al., 2008), and in prostate development, Hh signaling regulates
IGFBP-6 expression (Lipinski et al., 2005). Taken in conjunction
with our findings, this suggests that multiple mechanisms of
cross-regulation exist between Hh and IGF signaling. Gli-medi-
ated transcription acts through IGFBP3 to regulate apoptosis
and may also play a role in other developmental and neoplastic
processes. For instance, the finding that, in prostate cancer
cell lines, Hh blockade results in inhibition of IGF activity (Levitt
et al., 2007) might be explained by this mechanism.
In support of an important role for IGFBP3 and IGF signaling in
sarcomas, in vitro studies demonstrated growth inhibitory and
proapoptotic functions in Ewing’s sarcoma (Benini et al., 2006)
and osteosarcoma (Schmid et al., 2001) cell lines. In addition
to its effect in sarcoma cell lines, the use of recombinant IGFBP3
in other tumor types and in animal models of neoplasia resulting
in an anticancer effect is reported. (Butt et al., 2000; Jerome
et al., 2003, 2006; Rajah et al., 1997; Vokes et al., 2007). We
found that IGFBP3 primarily regulates apoptosis in chondrosar-
comas through inhibition of IGF signaling. Since inhibition of Hh
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the intriguing possibility that combined treatment with Hh
blockade may produce synergistic antitumor effects. Such a
treatment would be particularly important in chondrosarcoma,
as there are no universally effective chemotherapies for this
tumor type (Wunder et al., 2007). Furthermore, we found that
IGFBP3 expression is dramatically reduced in human cartilage
tumors and that its level of expression is lower in chondrosarco-
mas than in benign enchondromas. This raises the possibility
that the level of expression of IGFBP3 can be used as a prog-
nostic factor and a useful adjunct in the pathologic evaluation
of cartilage lesions for distinguishing between tumor grades.
EXPERIMENTAL PROCEDURES
Human Samples
Cartilage tumor samples and normal human growth plate cartilage were
prepared for organ culture or were cryopreserved immediately after surgical
Figure 7. IGFBP3 Regulates Chondrosarcoma Apoptosis
(A) Representative histologic sections showing TUNEL staining from organ
cultures of chondrosarcomas treated with IGFBP3 or carrier, showing a
substantial increase in apoptosis rate with IGFBP3. Arrow shows a TUNEL-
positive cell.
(B and C) Mean and 95% confidence intervals for the number of TUNEL-posi-
tive cells or active caspase-3-positive cells per high-powered field. There is
a statistically significant difference in TUNEL staining and caspase staining
with IGFBP3 treatment. An asterisk is above data that are significantly different
from the control.
(D) Mean and 95% confidence intervals for proportion of cells exhibiting an-
nexin V staining, as detected using flow cytometry in primary cell cultures
from a chondrosarcoma. siRNA for IGFBP3 brings the percentage of staining
in cells expressing p53 and treated with a Hh neutralizing antibody to baseline,
suggesting that the regulation of apoptosis by p53 and Hh signaling is medi-
ated by IGFBP3. An asterisk is above data that are significantly different
from control data.excision. The cryopreserved samples were used in a previous study of Hh
signaling, and additional clinical information has been reported elsewhere
(Tiet et al., 2006). Six chondrosarcoma samples were analyzed for explant
experiments, and each was analyzed in triplicate. An additional three chondro-
sarcoma samples were prepared as a primary cell culture, as reported else-
where (Wu et al., 2007). Informed consent was obtained from all patients prior
to surgery. These studies were approved by the Mount Sinai Hospital
Research Ethics Review Board and The Ethics Review Board Research Insti-
tute Hospital for Sick Children.
Mice
Amouse model of enchondromatosis in which the Hh-activated growth factor,
Gli2, is expressed in growth plate chondrocytes driven by the regulatory
elements of type two collagen, Tg(Gli2;ColIIAI), was used. Tumors develop
in these mice according to a molecular mechanism that is a common feature
in enchondromas; as such, these tumors are an applicable model for the
human disorder (Hopyan et al., 2002). rp53tm1Tyj mice (p53+/) mice (Jacks
et al., 1994) were crossed with Tg(Gli2;ColIIAI) mice, and progeny were bred
to generate Tg(Gli2;ColIIA1);p53/, Tg(Gli2;ColIIA1);p53+/, Tg(Gli2;ColIIA1);
p53+/+, p53+/, p53/, and wild-type littermates using a previously reported
crossing strategy (Poon et al., 2001). The tumor phenotype between at least
eight littermates of each genotype and age group were compared. Very few
Tg(Gli2;ColIIA1);p53/ or p53/ mice were available for analysis, and thus
they were excluded from our tumor phenotypic analysis. For analysis of fetal
limbs, mice at E16.5 were examined, and at least six mice of each genotype
or treatment condition were analyzed. Igf2tm1Rob (Igf+/) mice (DeChiara
et al., 1990) were crossed with Tg(Gli2;ColIIA1) mice in a similar manner to
generate Tg(Gli2;ColIIA1);Igf2+/ and Tg(Gli2;ColIIA1);Igf2+/+ mice. A mouse
protocol describing the above experimental procedures was approved by
the animal care committee of The Hospital for Sick Children.
Explant Analysis
Hind limbs from E16.5 embryos were placed in DMEM containing 0.1% BSA,
vitamin C (50 mg/ml), and Antibiotic-Antimycotic Solution (Wisent). One limb
from each embryo was treated with Hh ligand, IGFBP3, or IGF-1, whereas
the other acted as a control. Shh and anti-Hh antibody (monoclonal antibody,
Hybridoma Bank, University of Iowa, Iowa City, IA), cyclopamine, or tomata-
dine (a cyclopamine analog that lacks the ability to block Hh signaling as a
control) were used as reported elsewhere (Mau et al., 2007; Tiet et al., 2006).
Shh and the Hh antibody will cross-react to activate or inactivate Ihh signaling
(Tiet et al., 2006). Human or mouse recombinant IGFBP3 (2 mg/ml), IGF-I
neutralizing antibody (10 mg/ml), or IGF-II neutralizing antibody (10 mg/ml)
were obtained from R&D systems and utilized as reported elsewhere (Karey
and Sirbasku, 1988). The agents were used alone or in combination for three
consecutive days, with media changed each day replenishing the specific
agent utilized.
Histological Analysis, Immunohistochemistry, andWestern Analysis
Samples were fixed in 4% paraformaldehyde, treated with 20% EDTA for
decalcification, embedded in paraffin, and sectioned for histological evalua-
tion. Safranin O and hematoxylin and eosin staining was performed using stan-
dard techniques. ColX staining was used as a marker for chondrocyte terminal
differentiation, by incubating the sections with a 1:50 dilution of anti-human
recombinant ColX (Quartett Immunodiagnostika Biotechnologie GMBH) at
4C overnight. Proliferation in fetal limbs was assayed using a Ki-67 antibody
monoclonal antibody at a 1:50 dilution (DaykoCytochemical, M7249, Clone
TEC-3) at 4C overnight. Deparaffinized sections of decalcified mature limbs
were incubated with a 1:200 dilution of a phospho-histone H3 antibody (Sigma
Chemical Company, St. Louis) at 4C overnight and were counterstained with
hematoxylin. IGFBP3 protein was detected using a rabbit anti-mouse antibody
(Cell Sciences, Canton, MA, Cat #PAK-1) and incubated at a 1:300 dilution at
4C overnight. Western analysis for IRS was undertaken using an anti-phos-
pho Y612 IRS-1 antibody at a 1:1000 dilution (Abcam).
Caspase-3, TUNEL, and Annexin V Assays
Active Caspase-3 and TUNEL staining was used to detect apoptotic cells in
tissue sections. Deparaffinized sections were stained using an anti-active cas-
pase-3 antibody (Promega, Madison, WI, Cat #G7481) or using the ApoptagCancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc. 133
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cording to the manufacturer’s instructions. The proportion of cells exhibiting
annexin V staining was determined in cell cultures, using flow cytometry as
previously reported (Tjandra et al., 2007).
Cell Transfection and Reporter Constructs
A 1.8 kb IGFBP3 promoter construct driving luciferase (Cohick et al., 2000) was
transfected using lipofection. The QuikChange site-directed mutagenesis kit
(Stratagene) was used to mutate the putative Gli-binding site in this construct
as a negative control. Cells were then treatedwith cyclopamine, Shh ligand, Hh
antibody, or tomatadine (as a control) for 24 hr, and luciferase levels were
determined. A p53 expression vector was obtained from Clontech (Mountain
View, CA) and was transfected into primary chondrosarcomas (Itoh et al.,
2004). siRNA constructs for IGFBP3 (Santa Cruz, CA) were used as per the
manufacturer’s recommendations. A GFP-expressing construct was used to
identify successfully transfected cells for flow cytometry analysis.
Microarray Analysis
For gene profiling studies, the cell line was stably transfected with either the
R150C variant PTHR1 or a wild-type PTHR1, as previously reported (Mau
et al., 2007). RNA isolated from the samples was converted to double-
stranded cDNA using Superscript (GIBCO-Invitrogen) with a T7-(dT)24 primer,
which was then transcribed to biotinylated complementary RNA (cRNA) by
incorporating biotin-CTP and biotin-UTP using Enzo BioArray High Yield
RNA labeling kit (Enzo Diagnostics, New York). The cRNA labeling and hybrid-
izations were then performed according to Affymetrix GeneChip Protocol (Af-
fymetrix Inc., SantaClara, CA). The chips were scanned for fluorescence signal
detection. The experiment was performed in triplicate, and a 3-fold expression
difference was arbitrarily used as a threshold to detect differentially regulated
genes.
Figure 8. IGF Signaling Regulates Chondrocyte Apoptosis
and Cartilage Tumor Formation
(A) Western analysis for phosphorylated and total insulin receptor
substrate-1 (IRS-1) from protein extracts from various mouse geno-
types showing that IRS-1 phosphorylation level is increased in
Tg(Gli2;ColIIAI), p53/ and Tg(Gli2;ColIIAI);p53/ mice.
(B) Western analysis for phosphorylated IRS-1 in protein extracts from
chondrosarcoma explants treated with IGFBP3 or carrier showing
a lower phosphorylation level with IGFBP3 treatment.
(C and D) Mean and 95% confidence intervals for the number of
TUNEL-positive cells or caspase-positive cells in growth plates from
explant limbs of treated with IGFBP3 or neutralizing antibodies IGF-
1 and IGF-2, showing a similar change in apoptosis with use of the
neutralizing antibodies as with IGFBP3. An asterisk above a data point
shows a significant difference from control conditions.
(E and F) Mean and 95% confidence intervals for the number of
TUNEL-positive cells or caspase-positive cells per high-powered field
in chondrosarcoma explants treated with either IGFBP3 or IGF
neutralizing antibodies. An asterisk above a data point shows a signif-
icant difference from control conditions.
(G) The mean number and 95% confidence intervals of cartilage
lesions in the femur of Tg(Gli2;ColIIAI);Igf2+/ mice and Tg(Gli2;
ColIIAI);Igf2+/+ littermates. There was a substantial decline in the num-
ber of cartilage lesions that developed in the mice deficient in IGF2.
(H and I)Mean and 95%confidence intervals for the number of TUNEL-
or caspase-stained cells in growth plates from Tg(Gli2;ColIIAI);Igf2+/
mice and Tg(Gli2;ColIIAI);Igf2+/+ littermates. An asterisk above a
data point in (G)–(I) indicates a significant difference from Tg(Gli2;
ColIIAI);Igf2+/+ mice.
Real-Time Quantitative PCR
RNA was isolated from at least three independent experiments and
was analyzed in separate PCRs, with a minimum of triplicates for
each treatment condition and primer set. Gene expression between
samples was calculated using the 2DDCt method (Livak and Schmitt-
gen, 2001). Either the 28S rRNA or b-actin gene was used for target gene
normalization.
ChIP Analysis
ChIP assay was performed using the ChIP-IT kit (Active Motif) according to the
manufacturer’s protocol. Cells were fixed with 1% formaldehyde to preserve
protein/DNA interactions. The protein/DNA complex was then sheared with
eight pulses at power level two using a Sonic Dismembrator (Fisher Scientific)
of 10 s sonication followed by a 30 s rest on ice. A Gli2 rabbit polyclonal
antibody (Abcam) and negative control IgG (Active Motif) were used to immu-
noprecipitate the DNA/protein complex. Following immunoprecipitation,
crosslinking was reversed, the proteins were removed by treatment with
Proteinase K, and the DNA was purified and analyzed using PCR.
p53 Loss of Heterozygosity by PCR
Tumors in Tg(Gli2;ColIIAI);p53+/ mice were analyzed for loss of a p53 allele
using the same primers used for genotyping mice. DNA was extracted from
the tumor using GenElute Mammalian Genomic DNA Miniprep kit (Sigma,
Chemical Company, St. Louis) and subsequently analyzed by PCR.
Statistical Analysis
Means and 95% confidence intervals were calculated. The plus-or-minus sign
(±) is used in the text to show the 95% confidence intervals. The student t test
was used for comparison of data sets. A p value of <0.05 was used as
a threshold for statistical significance.
ACCESSION NUMBERS
Array data are deposited in the GEO database, accession number GSE15118
(http://www.ncbi.nlm.nih.gov/geo/).134 Cancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc.
Cancer Cell
Gli2 and p53 in Cartilage Tumor ProgressionACKNOWLEDGMENTS
This research is funded by the Canadian Institutes for Health Research (grant
37913). B.A.A. is supported by funds from the Canada Research Chairs
Program. We thank Dr. Brian Cox (Rossant Laboratory, The Hospital for Sick
Children, Toronto, ON, Canada) for his software advice and technical assis-
tance concerning sequence alignment and Dr. W. S. Cohick (Department of
Animal Sciences, Rutgers, The State University of New Jersey, New Bruns-
wick, NJ) for providing the IGFBP-3 promoter construct.
Received: October 17, 2008
Revised: March 7, 2009
Accepted: May 21, 2009
Published: August 3, 2009
REFERENCES
Amizuka, N., Warshawsky, H., Henderson, J.E., Goltzman, D., and Karaplis,
A.C. (1994). Parathyroid hormone-related peptide-depleted mice show
abnormal epiphyseal cartilage development and altered endochondral bone
formation. J. Cell Biol. 126, 1611–1623.
Ballock, R.T., and O’Keefe, R.J. (2003). Physiology and pathophysiology of the
growth plate. Birth Defects Res. C Embryo Today 69, 123–143.
Bar, E.E., Chaudhry, A., Farah, M.H., and Eberhart, C.G. (2007). Hedgehog
signaling promotes medulloblastoma survival via Bc/II. Am. J. Pathol. 170,
347–355.
Benini, S., Zuntini, M., Manara, M.C., Cohen, P., Nicoletti, G., Nanni, P., Oh, Y.,
Picci, P., and Scotlandi, K. (2006). Insulin-like growth factor binding protein 3
as an anticancer molecule in Ewing’s sarcoma. Int. J. Cancer 119, 1039–1046.
Bhattacharyya, N., Pechhold, K., Shahjee, H., Zappala, G., Elbi, C., Raaka, B.,
Wiench, M., Hong, J., and Rechler, M.M. (2006). Nonsecreted insulin-like
growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human
prostate cancer cells by IGF-independent mechanisms without being concen-
trated in the nucleus. J. Biol. Chem. 281, 24588–24601.
Bigelow, R.L., Chari, N.S., Unden, A.B., Spurgers, K.B., Lee, S., Roop, D.R.,
Toftgard, R., and McDonnell, T.J. (2004). Transcriptional regulation of bcl-2
mediated by the sonic hedgehog signaling pathway through gli-1. J. Biol.
Chem. 279, 1197–1205.
Butt, A.J., Firth, S.M., King, M.A., and Baxter, R.C. (2000). Insulin-like growth
factor-binding protein-3 modulates expression of Bax and Bcl-2 and potenti-
ates p53-independent radiation-induced apoptosis in human breast cancer
cells. J. Biol. Chem. 275, 39174–39181.
Cohick, W.S., Wang, B., Verma, P., and Boisclair, Y.R. (2000). Insulin-like
growth factor I (IGF-I) and cyclic adenosine 30,50-monophosphate regulate
IGF-binding protein-3 gene expression by transcriptional and posttranscrip-
tional mechanisms in mammary epithelial cells. Endocrinology 141, 4583–
4591.
Couvineau, A., Wouters, V., Bertrand, G., Rouyer, C., Ge´rard, B., Boon, L.M.,
Grandchamp, B., Vikkula, M., and Silve, C. (2008). PTHR1 mutations associ-
ated with Ollier disease result in receptor loss of function. Hum. Mol. Genet.
17, 2766–2775.
DeChiara, T.M., Efstratiadis, A., and Robertson, E.J. (1990). A growth-defi-
ciency phenotype in heterozygous mice carrying an insulin-like growth factor
II gene disrupted by targeting. Nature 345, 78–80.
Erenpreisa, J., and Roach, H.I. (1996). Epigenetic selection as a possible
component of transdifferentiation. Further study of the commitment of hyper-
trophic chondrocytes to become osteocytes. Mech. Ageing Dev. 87, 165–182.
Hopyan, S., Gokgoz, N., Poon, R., Gensure, R.C., Yu, C., Cole, W.G., Bell,
R.S., Juppner, H., Andrulis, I.L., Wunder, J.S., and Alman, B.A. (2002). A
mutant PTH/PTHrP type I receptor in enchondromatosis. Nat. Genet. 30,
306–310.
Itoh, K., Hase, H., Kojima, H., Saotome, K., Nishioka, K., and Kobata, T. (2004).
Central role of mitochondria and p53 in Fas-mediated apoptosis of rheumatoid
synovial fibroblasts. Rheumatology (Oxford) 43, 277–285.Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bronson,
R.T., andWeinberg, R.A. (1994). Tumor spectrum analysis in p53-mutant mice.
Curr. Biol. 4, 1–7.
Jenkins, P.J., Khalaf, S., Ogunkolade, W., McCarthy, K., David, T., Hands,
R.E., Davies, D., and Bustin, S.A. (2005). Differential expression of IGF-binding
protein-3 in normal and malignant colon and its influence on apoptosis.
Endocr. Relat. Cancer 12, 891–901.
Jerome, L., Shiry, L., and Leyland-Jones, B. (2003). Deregulation of the IGF
axis in cancer: epidemiological evidence and potential therapeutic interven-
tions. Endocr. Relat. Cancer 10, 561–578.
Jerome, L., Alami, N., Belanger, S., Page, V., Yu, Q., Paterson, J., Shiry, L.,
Pegram, M., and Leyland-Jones, B. (2006). Recombinant human insulin-like
growth factor binding protein 3 inhibits growth of human epidermal growth
factor receptor-2-overexpressing breast tumors and potentiates herceptin
activity in vivo. Cancer Res. 66, 7245–7252.
Kahn, A.J., and Simmons, D.J. (1977). Chondrocyte-to-osteocyte transforma-
tion in grafts of perichondrium-free epiphyseal cartilage. Clin. Orthop. Relat.
Res. 299–304.
Karaplis, A.C., Luz, A., Glowacki, J., Bronson, R.T., Tybulewicz, V.L.,
Kronenberg, H.M., and Mulligan, R.C. (1994). Lethal skeletal dysplasia from
targeted disruption of the parathyroid hormone-related peptide gene. Genes
Dev. 8, 277–289.
Karey, K.P., and Sirbasku, D.A. (1988). Differential responsiveness of human
breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estra-
diol. Cancer Res. 48, 4083–4092.
Kasper, M., Regl, G., Frischauf, A.M., and Aberger, F. (2006). GLI transcription
factors: mediators of oncogenic Hedgehog signalling. Eur. J. Cancer 42, 437–
445.
Kiepe, D., Ulinski, T., Powell, D.R., Durham, S.K., Mehls, O., and Tonshoff, B.
(2002). Differential effects of insulin-like growth factor binding proteins-1, 2,
3, and6 on cultured growth plate chondrocytes. Kidney Int. 62, 1591–1600.
Kim, H.S., Ingermann, A.R., Tsubaki, J., Twigg, S.M., Walker, G.E., and Oh, Y.
(2004). Insulin-like growth factor-binding protein 3 induces caspase-depen-
dent apoptosis through a death receptor-mediated pathway in MCF-7 human
breast cancer cells. Cancer Res. 64, 2229–2237.
Kobayashi, T., Chung, U.I., Schipani, E., Starbuck, M., Karsenty, G., Katagiri,
T., Goad, D.L., Lanske, B., and Kronenberg, H.M. (2002). PTHrP and Indian
hedgehog control differentiation of growth plate chondrocytes at multiple
steps. Development 129, 2977–2986.
Komarova, E.A., Zelnick, C.R., Chin, D., Zeremski, M., Gleiberman, A.S.,
Bacus, S.S., and Gudkov, A.V. (1997). Intracellular localization of p53 tumor
suppressor protein in gamma-irradiated cells is cell cycle regulated and deter-
mined by the nucleus. Cancer Res. 57, 5217–5220.
Koziel, L., Wuelling, M., Schneider, S., and Vortkamp, A. (2005). Gli3 acts as
a repressor downstream of Ihh in regulating two distinct steps of chondrocyte
differentiation. Development 132, 5249–5260.
Lanske, B., Karaplis, A.C., Lee, K., Luz, A., Vortkamp, A., Pirro, A., Karperien,
M., Defize, L.H., Ho, C., Mulligan, R.C., et al. (1996). PTH/PTHrP receptor in
early development and Indian hedgehog-regulated bone growth. Science
273, 663–666.
Lee, H.Y., Chun, K.H., Liu, B.,Wiehle, S.A., Cristiano, R.J., Hong,W.K., Cohen,
P., and Kurie, J.M. (2002). Insulin-like growth factor binding protein-3 inhibits
the growth of non-small cell lung cancer. Cancer Res. 62, 3530–3537.
Lee, K.W., Ma, L., Yan, X., Liu, B., Zhang, X.K., and Cohen, P. (2005). Rapid
apoptosis induction by IGFBP-3 involves an insulin-like growth factor-inde-
pendent nucleomitochondrial translocation of RXRalpha/Nur77. J. Biol.
Chem. 280, 16942–16948.
Levitt, R.J., Zhao, Y., Blouin, M.J., and Pollak, M. (2007). The hedgehog
pathway inhibitor cyclopamine increases levels of p27, and decreases both
expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer
Lett. 255, 300–306.
Lipinski, R.J., Cook, C.H., Barnett, D.H., Gipp, J.J., Peterson, R.E., and
Bushman, W. (2005). Sonic hedgehog signaling regulates the expression ofCancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc. 135
Cancer Cell
Gli2 and p53 in Cartilage Tumor Progressioninsulin-like growth factor binding protein-6 during fetal prostate development.
Dev. Dyn. 233, 829–836.
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.
Methods 25, 402–408.
Louro, I.D., Bailey, E.C., Li, X., South, L.S., McKie-Bell, P.R., Yoder, B.K.,
Huang, C.C., Johnson, M.R., Hill, A.E., Johnson, R.L., and Ruppert, J.M.
(2002). Comparative gene expression profile analysis of GLI and c-MYC in
an epithelial model of malignant transformation. Cancer Res. 62, 5867–5873.
MacLean, H.E., Kim, J.I., Glimcher, M.J., Wang, J., Kronenberg, H.M., and
Glimcher, L.H. (2003). Absence of transcription factor c-maf causes abnormal
terminal differentiation of hypertrophic chondrocytes during endochondral
bone development. Dev. Biol. 262, 51–63.
Mau, E., Whetstone, H., Yu, C., Hopyan, S., Wunder, J.S., and Alman, B.A.
(2007). PTHrP regulates growth plate chondrocyte differentiation and prolifer-
ation in a Gli3 dependent manner utilizing hedgehog ligand dependent and
independent mechanisms. Dev. Biol. 305, 28–39.
Morton, J.P., Mongeau, M.E., Klimstra, D.S., Morris, J.P., Lee, Y.C., Kawaguchi,
Y., Wright, C.V., Hebrok, M., and Lewis, B.C. (2007). Sonic hedgehog acts at
multiple stages during pancreatic tumorigenesis. Proc. Natl. Acad. Sci. USA
104, 5103–5108.
Olney, R.C., and Mougey, E.B. (1999). Expression of the components of the
insulin-like growth factor axis across the growth-plate. Mol. Cell. Endocrinol.
156, 63–71.
Oshiro, Y., Chaturvedi, V., Hayden, D., Nazeer, T., Johnson, M., Johnston,
D.A., Ordonez, N.G., Ayala, A.G., and Czerniak, B. (1998). Altered p53 is asso-
ciated with aggressive behavior of chondrosarcoma: a long term follow-up
study. Cancer 83, 2324–2334.
Parathath, S.R., Mainwaring, L.A., Fernandez, L.A., Campbell, D.O., and
Kenney, A.M. (2008). Insulin receptor substrate 1 is an effector of sonic
hedgehog mitogenic signaling in cerebellar neural precursors. Development
135, 3291–3300.
Parker, E.A., Hegde, A., Buckley, M., Barnes, K.M., Baron, J., and Nilsson, O.
(2007). Spatial and temporal regulation of GH-IGF-related gene expression in
growth plate cartilage. J. Endocrinol. 194, 31–40.
Poon, R., Smits, R., Li, C., Jagmohan-Changur, S., Kong, M., Cheon, S., Yu,
C., Fodde, R., and Alman, B.A. (2001). Cyclooxygenase-two (COX-2) modu-
lates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 20,
451–460.
Rajah, R., Valentinis, B., and Cohen, P. (1997). Insulin-like growth factor (IGF)-
binding protein-3 induces apoptosis and mediates the effects of transforming
growth factor-beta1 on programmed cell death through a p53- and IGF-inde-
pendent mechanism. J. Biol. Chem. 272, 12181–12188.
Reinke, V., and Lozano, G. (1997). Differential activation of p53 targets in cells
treated with ultraviolet radiation that undergo both apoptosis and growth
arrest. Radiat. Res. 148, 115–122.
Schmid, C., Ghirlanda-Keller, C., and Zapf, J. (2001). Effects of IGF-I and -II,
IGF binding protein-3 (IGFBP-3), and transforming growth factor-beta136 Cancer Cell 16, 126–136, August 4, 2009 ª2009 Elsevier Inc.(TGF-beta) on growth and apoptosis of human osteosarcoma Saos-2/B-10
cells: lack of IGF-independent IGFBP-3 effects. Eur. J. Endocrinol. 145,
213–221.
Shim, M.L., Levitt Katz, L.E., Davis, J., Dotzler, W.C., Cohen, P., and Ferry,
R.J., Jr. (2004). Insulin-like growth factor binding protein-3 is a novel mediator
of apoptosis in insulin-secreting cells. Growth Horm. IGF Res. 14, 216–225.
Silha, J.V., Sheppard, P.C., Mishra, S., Gui, Y., Schwartz, J., Dodd, J.G., and
Murphy, L.J. (2006). Insulin-like growth factor (IGF) binding protein-3 attenu-
ates prostate tumor growth by IGF-dependent and IGF-independent mecha-
nisms. Endocrinology 147, 2112–2121.
Spagnoli, A., Hwa, V., Horton, W.A., Lunstrum, G.P., Roberts, C.T., Jr.,
Chiarelli, F., Torello, M., and Rosenfeld, R.G. (2001). Antiproliferative effects
of insulin-like growth factor-binding protein-3 in mesenchymal chondrogenic
cell line RCJ3.1C5.18. relationship to differentiation stage. J. Biol. Chem.
276, 5533–5540.
Srinivasula, S.M., Ahmad, M., MacFarlane, M., Luo, Z., Huang, Z., Fernandes-
Alnemri, T., and Alnemri, E.S. (1998). Generation of constitutively active
recombinant caspases-3 and 6 by rearrangement of their subunits. J. Biol.
Chem. 273, 10107–10111.
Tiet, T.D., Hopyan, S., Nadesan, P., Gokgoz, N., Poon, R., Lin, A.C., Yan, T.,
Andrulis, I.L., Alman, B.A., and Wunder, J.S. (2006). Constitutive hedgehog
signaling in chondrosarcoma up-regulates tumor cell proliferation. Am. J.
Pathol. 168, 321–330.
Tjandra, S.S., Hsu, C., Goh, Y.I., Gurung, A., Poon, R., Nadesan, P., and
Alman, B.A. (2007). IFN-{beta} signaling positively regulates tumorigenesis in
aggressive fibromatosis, potentially by modulating mesenchymal progenitors.
Cancer Res. 67, 7124–7131.
Villafuerte, B.C., Zhao, W., Herington, A.C., Saffery, R., and Phillips, L.S.
(1997). Identification of an insulin-responsive element in the rat insulin-like
growth factor-binding protein-3 gene. J. Biol. Chem. 272, 5024–5030.
Vokes, S.A., Ji, H., McCuine, S., Tenzen, T., Giles, S., Zhong, S., Longabaugh,
W.J., Davidson, E.H., Wong, W.H., and McMahon, A.P. (2007). Genomic char-
acterization of Gli-activator targets in sonic hedgehog-mediated neural
patterning. Development 134, 1977–1989.
Vortkamp, A., Lee, K., Lanske, B., Segre, G.V., Kronenberg, H.M., and Tabin,
C.J. (1996). Regulation of rate of cartilage differentiation by Indian hedgehog
and PTH-related protein. Science 273, 613–622.
Wu, C., Wei, Q., Utomo, V., Nadesan, P., Whetstone, H., Kandel, R., Wunder,
J.S., and Alman, B.A. (2007). Side population cells isolated frommesenchymal
neoplasms have tumor initiating potential. Cancer Res. 67, 8216–8222.
Wunder, J.S., Nielsen, T.O., Maki, R.G., O’Sullivan, B., and Alman, B.A. (2007).
Opportunities for improving the therapeutic ratio for patients with sarcoma.
Lancet Oncol. 8, 513–524.
Yamanaka, Y., Wilson, E.M., Rosenfeld, R.G., and Oh, Y. (1997). Inhibition
of insulin receptor activation by insulin-like growth factor binding proteins.
J. Biol. Chem. 272, 30729–30734.
